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Abstract: We have synthesized and examined the antibacterial activity, toxicity and 
affinity towards bacterial type II topoisomerases of a series of 1,2,4-triazole-ciprofloxacin 
hybrids. A number of these compounds displayed enhanced activity against Gram-positive 
and Gram-negative bacteria when compared to ciprofloxacin. The toxic concentrations of 
the obtained derivatives, evaluated on HEK-293 cells using MTT assay, were much higher 
than concentrations required to produce antibacterial effect. Finally, the results of 
enzymatic studies showed that the analyzed compounds demonstrated other preferences as 
regards primary and secondary molecular targets than ciprofloxacin. 
Keywords: fluoroquinolones; gyrase DNA; topoisomerase IV; topoisomerase inhibitors; 
MTT assay 
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1. Introduction 
A chance discovery of nalidixic acid, being a by-product in the synthesis of chloroquine, initiated 
the development of antibacterial drugs known as (fluoro)quinolones. Chemotherapeutics from the 
(fluoro)quinolones group characterize with a broad-spectrum of antibacterial effect, including  
Gram-positive and Gram-negative bacteria, mycobacteria and so-called atypical bacteria. These drugs 
are used in the treatment of respiratory, urinary, and alimentary systems infections, sexually transmitted 
diseases, and skin, soft tissues, bones and joints infections [1]. Besides the broad-spectrum of activity, 
the clinical success of fluoroquinoles is due to such features as good bioavailability after oral 
administration, good tissue penetration, beneficial pharmacokinetics and relatively low toxicity [2]. 
Even so, the global phenomenon of bacteria’s resistance to antibiotics affects fluoroquinoles as well. 
The first bacterial strains which demonstrated reduced sensitivity to fluoroquinolones were 
Staphylococcus aureus (including the MRSA strain) and Pseudomonas aeruginosa [3]. Some scientists 
claim that between 95% and 100% of the MRSA strains are resistant to the drugs from this group [4]. 
Moreover, since the 1990s, resistance to fluoroquinolones has increased also in the case of other 
Gram-positive and Gram-negative bacteria. For instance, the percentage of Escherichia coli isolates 
resistant to fluoroquinolones in Great Britain has increased during just five years, from 2001–2006, 
from 6%–20% [5]. In most cases, the rate of increased resistance is correlated with the amount of 
fluoroquinolones usage. Bacterial resistance may have different backgrounds, and the most frequently 
named mechanisms include: (i) target-site mutation; (ii) enzymatic degradation of the drug; (iii) reduced 
permeability of the drug; and (iv) active export of the drug through efflux pumps. However, 
irrespective of its molecular background, fluoroquinolone resistance compels the search for new 
representatives of this group characterized by strong antibacterial activity and ability to overcome 
bacterial resistance. As it has been proven quite recently, a novel class of fluoroquinolones obtained by 
molecular hybridization of ciprofloxacin and different 1,2,4-triazole derivatives demonstrate a 
promising antibacterial activity against both Gram-positive and Gram-negative bacteria [6]. The results 
showed that the chemical character of substituents connected to the 1,2,4-triazole ring affected the 
antibacterial activity of such compounds. The most beneficial effect was obtained when the triazole 
ring was connected with a hydroxyphenyl fragment. This may suggest that the hydroxyl group 
promotes hydrogen bonding with target enzymes. On the other hand, a disubstitution pattern of the 
second aryl substituent seemed to be also relevant for antibacterial potency. As the published results 
are quite preliminary, more detailed description of the relationship(s) between the antibacterial activity 
and chemical structure shall require a greater number of the synthesized derivatives. Moreover, there is 
no data that would explain the reasons for increased activity of 1,2,4-triazole-ciprofloxacin hybrids as 
compared with the activity of the ciprofloxacin alone. Therefore, to shed some light on the molecular 
grounds of this phenomenon, the enzymatic tests were carried out with the use of different enzymatic 
models obtained from Escherichia coli and Staphylococcus aureus. It was also checked if the 
antibacterial effect of the tested compounds resulted from selective toxicity towards bacterial cells. 
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2. Results and Discussion 
2.1. Chemistry 
The title 1,2,4-triazole-ciprofloxacin hybrids were synthesized according to previously published 
procedure [6], in the reaction of respective 4,5-disubstituted 1,2,4-triazole-3-thiones, ciprofloxacin and 
formaldehyde. Substitution pattern of substituents in the 1,2,4-triazole ring is listed in Scheme 1. 
(1-21) (22-42)
EtOH, HCHO
stirring, 12h
Ciprofloxacin
 
Scheme 1. Synthetic route to compounds 22–42. List of substituents: 1, 22. R1 = 2-OH,  
R2 = cyclohexyl; 2, 23. R1 = 2-OH, R2 = 3,4-diCl-C6H3-; 3, 24. R1 = 2-OH, R2 = 2,4-diCl-
C6H3-; 4, 25. R1 = 2-OH, R2 = 3,5-diCl-C6H3-; 5, 26. R1 = 2-OH, R2 = 2-Cl-4-Br-C6H3-; 6, 
27. R1 = 2-OH, R2 = 3-Cl-4-CH3-C6H3-; 7, 28. R1 = 2-OH, R2 = 3-CF3-4-Cl-C6H3-; 8, 29. 
R1 = 3-OH, R2 = cyclohexyl; 9, 30. R1 = 3-OH, R2 = 3,4-diCl-C6H3-; 10, 31. R1 = 3-OH, 
R2 = 2,4-diCl-C6H3-; 11, 32. R1 = 3-OH, R2 = 3,5-diCl-C6H3-; 12, 33. R1 = 3-OH,  
R2 = 2-Cl-4-Br-C6H3-; 13, 34. R1 = 3-OH, R2 = 3-Cl-4-CH3-C6H3-; 14, 35. R1 = 3-OH,  
R2 = 3-CF3-4-Cl-C6H3-; 15, 36. R1 = 4-OH, R2 = cyclohexyl; 16, 37. R1 = 4-OH,  
R2 = 3,4-diCl-C6H3-; 17, 38. R1 = 4-OH, R2 = 2,4-diCl-C6H3-; 18, 39. R1 = 4-OH,  
R2 = 3,5-diCl-C6H3-; 19, 40. R1 = 4-OH, R2 = 2-Cl-4-Br-C6H3-; 20, 41. R1 = 4-OH,  
R2 = 3-Cl-4-CH3-C6H3-; 21, 42. R1 = 4-OH, R2 = 3-CF3-4-Cl-C6H3-. 
2.2. Antibacterial Activity 
The antibacterial activity of compounds (22–42) was tested on Gram-positive and Gram-negative 
strains. As it is shown in Tables 1 and 2, the majority of novel hybrids obtained by a molecular 
hybridization of ciprofloxacin (CPX) and different 1,2,4-triazole derivatives were far more active than 
the initial antibiotic. What is important, the enhanced antibacterial effect concerned both Gram-positive 
and Gram-negative bacteria. This is even more important as the chemical modifications of 
fluoroquinolones resulting in the increase of activity towards one type of bacteria (e.g., Gram-positive 
or Gram-negative ones) usually are connected with a decrease of activity towards another type of 
bacteria [7,8]. It results, most probably, from the differences in the structure of the primary molecular 
target which, in case of Gram-negative bacteria is DNA gyrase (gyrDNA), and in case of Gram-positive 
bacteria—topoisomerase IV (topoIV) [9]. In the group of Gram-negative bacteria all derivatives tested 
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demonstrated stronger than CPX effect on pathogenic strains P. aeruginosa and K. pneumoniae. The 
strongest inhibitory effect on the growth of P. aeruginosa ATCC9027 was demonstrated by the 
derivatives with the 2,4-disubstituted phenyl ring connected to the 1,2,4-triazole skeleton. The 
antibacterial activity of such derivatives was around nine times higher than CPX alone. Moreover, 
compound (40) completely inhibited the growth of K. pneumoniae ATCC13883 at the concentration 
about 18 times lower than in the case of CPX. Similar activity was also demonstrated by  
3,4-dichlorophenyl derivative (37). Most of the synthesized compounds, moreover, demonstrated 
strong antibacterial effect against the remaining two Gram-negative strains (i.e., E. coli ATCC25922 
and P. mirabilis ATCC 12453). As MIC values for Gram-negative bacteria indicate, the presence of 
the aromatic ring connected to the 1,2,4-triazole core (at nitrogen atom) is not required to obtain 
significant antibacterial activity. In most cases, respective cyclohexyl derivatives (22, 29, 36) also 
demonstrated stronger antibacterial effect than CPX. Similarly, the change of a hydroxyl group position 
(ortho-, meta-, para-) in another phenyl ring affected the change of activity to a slight degree only. 
However, its presence alone is significant, which has been confirmed by the previously obtained 
results [6]. 
Table 1. Antibacterial activity of compounds 22–42 against Gram-negative strains. 
Compounds 
Minimal Inhibitory Concentrations (µM) 
E. coli 
ATCC 25922 
K. pneumoniae 
ATCC 13883 
P. mirabilis 
ATCC 12453 
P. aeruginosa 
ATCC 9027 
22 0.012 0.048 0.024 0.384 
23 0.011 0.088 0.022 0.176 
24 0.011 0.088 0.044 0.176 
25 0.011 0.176 0.022 0.352 
26 0.01 0.16 0.08 0.32 
27 0.011 0.045 0.045 0.18 
28 0.01 0.042 0.021 0.084 
29 0.048 0.096 0.096 0.384 
30 0.022 0.088 0.022 0.176 
31 0.044 0.088 0.022 0.176 
32 0.022 0.088 0.044 0.176 
33 0.01 0.04 0.02 0.08 
34 0.011 0.045 0.023 0.18 
35 0.021 0.042 0.021 0.17 
36 0.048 0.096 0.096 0.192 
37 0.011 0.022 0.022 0.352 
38 0.011 0.044 0.022 0.352 
39 0.352 0.044 0.176 0.704 
40 0.01 0.02 0.04 0.08 
41 0.011 0.18 0.023 0.18 
42 0.01 0.042 0.021 0.084 
CPX 0.024 0.36 0.045 0.72 
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Table 2. Antibacterial activity of compounds 22–42 against Gram-positive strains 
Compounds 
Minimal Inhibitory Concentrations (µM) 
MSSA-1 * MSSA-2 ** MRSA *** 
S. epidermidis 
ATCC 12228 
B. subtilis 
ATCC 6638 
B. cereus 
ATCC 10876 
M. luteus 
ATCC 10240 
22 1.58 0.40 0.40 0.40 0.10 0.19 3.16 
23 0.35 0.35 0.18 0.04 0.04 0.18 1.40 
24 0.18 0.09 0.09 0.045 0.35 0.045 1.40 
25 0.09 0.09 0.045 0.18 0.09 0.09 0.70 
26 0.33 0.165 0.083 0.041 0.083 0.165 1.32 
27 0.74 0.18 0.18 0.09 0.09 0.18 1.48 
28 0.34 0.17 0.17 0.084 0.084 0.17 1.36 
29 3.16 1.58 1.58 0.79 0.79 0.79 6.32 
30 0.35 0.35 0.18 0.09 0.09 0.18 1.40 
31 0.35 0.18 0.09 0.35 0.18 0.18 1.40 
32 0.70 0.18 0.18 0.35 0.18 0.18 1.40 
33 0.165 0.165 0.165 0.041 0.041 0.165 1.32 
34 0.36 0.09 0.09 0.18 0.09 0.18 0.74 
35 0.68 0.084 0.17 0.17 0.042 0.17 1.36 
36 3.16 1.58 1.58 1.58 0.024 0.20 3.91 
37 0.35 0.18 0.35 0.18 0.045 0.18 0.70 
38 0.70 0.18 0.18 0.35 0.045 0.18 1.40 
39 5.60 1.40 2.80 0.35 0.35 0.70 22.9 
40 0.33 0.083 0.083 0.165 0.041 0.165 0.66 
41 0.36 0.18 0.18 0.36 0.18 0.36 0.74 
42 0.68 0.084 0.17 0.17 0.042 0.17 1.36 
CPX 2.96 0.72 - 1.48 0.09 0.36 5.88 
Vancomycin - - 0.68 - - - - 
“*”–S. aureus ATCC 25923, “**”–S. aureus ATCC 6538, “***”–S. aureus MIKROBANK 14001. 
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In case of Gram-positive bacteria (Table 2), unlike the tested Gram-negative ones, the structure of 
the substituent attached to the nitrogen atom in the 1,2,4-triazole ring is of much greater importance. 
Especially in staphylococci it is clearly discernible that the presence of disubstituted phenyl ring is 
much more beneficial than the presence of cycloalkyl substituent. Respective cyclohexyl derivatives 
(22, 29, 36), although they still acted at least equally as strong as CPX, demonstrated weaker activity 
than other CPX-triazole hybrids. Among significant merits of the newly-obtained compounds, one 
should name the fact that methicillin-resistant S. aureus (MRSA) strain was particularly sensitive to 
their effect. Among ortho-, meta- and para-hydroxyphenyl derivatives there were compounds with at 
least a few times stronger antibacterial activity than vancomycin—the antibiotic used in treating heavy 
infections caused by MRSA. For instance, compounds 24, 26, 31, 34 and 40 inhibited the growth of 
the tested MRSA strain about eight times stronger than vancomycin, while the antibacterial activity of 
3,5-dichlorophenyl derivative (25) was as much as 15 times’ stronger than the activity of the 
previously mentioned antibiotic. The same compound (i.e., compound 25) proved to be potent against 
other staphylococci tested, i.e., against MSSA-1 and S. epidermidis. It suggests that such a substitution 
pattern at the phenyl rings is beneficial from the microbiological point of view. On the other hand, the 
differences in activity of the respective 3,5-dichlorosubstituted derivatives (25, 32, 39) prove that the 
strength of antibacterial activity of CPX-triazole hybrids on staphylococci is determined by the 
structure of both aromatic substituents connected to the 1,2,4-triazole ring. Among the two bacilli 
strains used in our studies, greater clinical significance is demonstrated by the Bacillus cereus, since it 
may be the cause of dangerous food poisoning and in children it may also lead to meningitis [10,11]. 
In most cases the antibacterial activity of novel CPX-triazole hybrids against B. cereus ATCC10876 
was higher than the activity of CPX alone. It is also of significance that B. cereus is used as a model 
strain in the research in relation to new drugs against anthrax as it is closely related genetically to 
Bacillus anthracis. Thus, one can assume that the compounds effective against B. cereus might also be 
equally effective in the treatment of anthrax. 
2.3. Toxicity Evaluation 
The antibacterial activity of newly synthesized compounds may be the result of their selective effect 
on bacterial cells or it may result from non-selective toxicity addressed to any live cells (including the 
human ones). In the latter case, respective compounds should be disqualified from among the potential 
antibacterial drugs, since the concentration which inhibits the growth of bacterial cells cannot disturb 
the normal functioning of host cells or tissues. In our studies, human embryonic kidney cells (HEK-293) 
were used to evaluate the cytotoxicity of the selected CPX-triazole hybrids, using the MTT test as a 
marker of cells viability Table 3). Toxicity profile of potential antibacterials may be characterized by 
the ratio of EC50/MIC [12]. The bigger the gap between EC50 and MIC values, the lesser the risk of 
toxic effects. In the cases of all investigated derivatives, (i.e., 23–28, 33, 34, 39, 40) the median 
effective concentrations, i.e. such concentrations of the substance which inhibit cell growth in 50%, in 
proportion to the growth of control cells, were much higher than the concentrations causing 
antibacterial effect (Table 3). Due to low antibacterial activity of the tested compounds against M. luteus 
ATCC10240, the EC50/MIC ratio for that strain fell within the range between two and 128. On the 
other hand, the lowest risk of toxic effects was observed with the use of newly-obtained derivatives 
Molecules 2015, 20 6260 
 
 
against E. coli ATCC25922 cells. In the case of this particular strain, the EC50 values were from  
1184 to 12334 times higher than the respective MICs. The lowest toxicity against human cells HEK-293 
was demonstrated by compound 28, obtained from 4-[4-chloro-3-(trifluoromethyl)phenyl]-5-(2-
hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione. When one compares its toxicity and the 
toxicity of compounds 23 and 27 (also possessing 3,4-disubstituted phenyl ring attached to 1,2,4-triazole 
core), it is clearly discernible that the effect on human cells’ viability depends rather on the presence of 
specific substituents in the molecule (in this case CF3 group) than on the substitution pattern of the 
phenyl ring. 
Table 3. Toxic effects of the selected triazole-CPX hybrids towards human HEK-293 cells. 
Compounds EC50 ± SD (µM) EC50/MIC (Range) 
23 47.98 ± 10.61 4362–34 
24 59.57 ± 15.92 5415–43 
25 50.47 ± 3.95 4588–72 
26 55.23 ± 9.74 5020–42 
27 43.26 ± 4.28 3933–29 
28 123.34 ± 2.67 12334–90 
33 76.58 ± 9.74 7658–58 
34 64.74 ± 6.41 5885–87 
39 52.09 ± 15.08 1184–2 
40 84.16 ± 14.61 8416–128 
2.4. Affinity of the Selected CPX-Triazole Hybrids towards Bacterial Type II Topoisomerases 
As it is already known, fluoroquinolones demonstrate affinity towards bacterial type II topoisomerases 
(i.e., DNA gyrase and topoisomerase IV). Both literature data [13], as well as the results of our 
research (Table 4) prove that among Gram-negative bacteria the primary molecular target for CPX is 
DNA gyrase. The inhibition of topoIV by CPX is only an additional mechanism conditioning the 
antibacterial activity of that fluoroquinolone. Whereas in case of Gram-positive bacteria, topoIV is the 
primary molecular target for CPX, and DNA gyrase only plays a secondary role. Taking into account 
the above-mentioned differences in the structure of primary molecular targets among Gram-positive 
and Gram-negative bacteria, the analysis of affinity of the synthesized derivatives was performed with 
the use of topoisomerases isolated from S. aureus and E. coli. The results presented in Table 4 show 
that the analyzed compounds (24, 25, 39) demonstrate other preferences as regards primary and 
secondary molecular targets than CPX. There is a visible weakening of affinity towards the main 
molecular targets with a simultaneous increase towards molecular targets deemed to be secondary. So, 
compounds 25 and 39 demonstrated increased affinity towards topoisomerase IV isolated from E. coli, 
whereas compounds 24 and 39 showed increased affinity towards DNA gyrase isolated from S. aureus. 
Moreover, the results of enzymatic assays have proven that stronger antibacterial activity of novel 
CPX derivatives (as compared to CPX alone) cannot be caused by the increased affinity towards 
bacterial type II topoisomerases. It seems hardly likely that such a significant decrease of affinity (e.g., 
from 0.15–3.5 μM for compound 24) towards the primary molecular targets may be compensated with 
a slightly increased affinity to the respective secondary targets. Moreover, it looks obvious that the 
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affinity of the synthesized compounds towards bacterial type II topoisomerases depends on the 
structure of both substituents connected to the 1,2,4-triazole skeleton. 
Table 4. Affinity of the selected triazole-CPX hybrids towards bacterial type II topoisomerases 
obtained from Escherichia coli and Staphylococcus aureus. 
 IC50 [μM] 
 Escherichia coli Staphylococcus aureus 
 gyrDNA topoIV gyrDNA topoIV 
24 3.5 80.0 55.0 15.5 
25 1.2 56.0 164.0 19.0 
39 3.2 66.0 68.0 22.0 
Ciprofloxacin 0.15 80.0 >100.0 4.0 
The comparison of IC50 values for two 2-hydroxyphenyl derivatives (24, 25) showed that the 
substitution pattern of the second phenyl ring connected to the 1,2,4-triazole ring had an important 
effect on the affinity to DNA gyrase, both among Gram-positive and Gram-negative bacteria. The 
change of location of the hydroxyl group in hydroxyphenyl moiety had also strong influence on the 
functioning of DNA gyrase. 
Summarizing, one may state that the increased antibacterial activity of the newly synthesized  
CPX-triazole hybrids (22–42) is probably a sum of different factors and the changed affinity of such 
compounds to primary and secondary molecular targets is only one of them. Moreover, one should also 
consider the possibility of increased permeability of these types of compounds into bacterial cells or 
their reduced susceptibility to endogenous efflux systems. Possible existence of an additional, so far 
unknown, mechanism of antibacterial action of these compounds should not be excluded. 
3. Experimental Section  
3.1. Chemistry 
3.1.1. General Comments 
All reagents and solvents were purchased from Alfa Aesar (Ward Hill, MA, USA) and  
Merck Co. (Darmstadt, Germany). Melting points were determined by using Fisher-Johns apparatus 
(Fisher Scientific, Schwerte, Germany) and are uncorrected. The 1H-NMR and 13C-NMR spectra (in 
DMSO-d6) were recorded on a Bruker Avance spectrometer (Bruker BioSpin GmbH, Rheinstetten, 
Germany) using TMS as an internal standard. FT-IR spectra were recorded using an ATR Platinum 
Diamond A 225 device. Elemental analyses were performed on an AMZ 851 CHX analyzer (PG, 
Gdańsk, Poland) and the results were within ±0.4% of the theoretical value. 
3.1.2. General Procedure for the Synthesis of 1,2,4-Triazole-3-Thione Derivatives (1–21) 
Compounds 1–21 were prepared by intramolecular cyclization of 1-(hydroxybenzoyl)-4-substituted 
thiosemicarbazides [14]. These compounds were dissolved in 2% NaOH and refluxed for 2 h. After 
cooling, the mixture was neutralized with 3M HCl. The precipitate formed was filtered and washed 
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with distilled water. The compounds were crystallized from EtOH. In the cases of already known 
compounds, information about their properties may be retrieved in the Chemical Abstract Service 
database (CAS numbers are given below). 
4-Cyclohexyl-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (1). Yield: 82%. CAS: 
26028-72-8. 
4-(3,4-Dichlorophenyl)-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (2). Yield: 87%, 
m.p. 258–260 °C, 1H-NMR (250 MHz): 6.77–7.74 (m, 7H, Ar-H), 10.08 (s, 1H, OH), 14.21 (s, 1H, 
NH). 13C-NMR (75 MHz): 111.30, 114.25, 117.80, 126.82, 128.68, 129.11, 129.30, 130.25, 131.18, 
132.89, 148.18, 153.98, 166.00. Anal. calc. for C14H9Cl2N3OS (338.21): C 49.72, H 2.68, N 12.42. 
Found: C 49.58, H 2.56, N 12.27. 
4-(2,4-Dichlorophenyl)-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (3). Yield: 84%, 
m.p. 188–189 °C, 1H-NMR (250 MHz): 6.78–7.05 (m, 2H, Ar-H), 7.25–7.60 (m, 4H, Ar-H), 7.68–7.81 
(m, 1H, Ar-H), 10.16 (s, 1H, OH), 14.24 (s, 1H, NH). 13C-NMR (75 MHz): 111.03, 114.33, 117.57, 
126.52, 128.06, 129.67, 129.90, 131.18, 131.45, 131.71, 133.69, 148.39, 154.24, 166.51. Anal. calc. 
for C14H9Cl2N3OS (338.21): C 49.72, H 2.68, N 12.42. Found: C 49.60, H 2.53, N 12.31. 
4-(3,5-Dichlorophenyl)-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (4). Yield: 81%, 
m.p. 194–196 °C, 1H-NMR (250 MHz): 6.79–7.06 (m, 2H, Ar-H), 7.31–7.55 (m, 4H, Ar-H), 7.70–7.76 
(m, 1H, Ar-H), 10.17 (s, 1H, OH), 14.24 (s, 1H, NH). 13C-NMR (75 MHz): 111.28, 114.33, 117.71, 
125.71, 127.31, 130.31, 131.19, 132.04, 135.19, 148.09, 154.22, 166.15. Anal. calc. for C14H9Cl2N3OS 
(338.21): C 49.72, H 2.68, N 12.42. Found: C 49.64, H 2.50, N 12.34. 
4-(4-Bromo-2-chlorophenyl)-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (5). Yield: 
80%. CAS: 896077-18-2. 
4-(3-Chloro-4-methylphenyl)-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (6). Yield: 
78%, m.p. 236–238 °C, 1H-NMR (250 MHz): 2.34 (s, 3H, CH3), 6.78–6.94 (m, 2H, Ar-H), 7.12–7.18 
(m, 1H, Ar-H), 7.27–7.47 (m, 4H, Ar-H), 10.08 (s, 1H, OH), 14.20 (s, 1H, NH). 13C-NMR (75 MHz): 
17.88, 111.62, 114.20, 117.67, 125.11, 126.86, 129.59, 130.21, 130.97, 131.14, 131.83, 134.96, 
148.23, 154.23, 166.15. Anal. calc. for C15H12ClN3OS (317.79): C 56.69, H 3.81, N 13.22. Found: C 
56.45, H 3.75, N 13.02. 
4-[4-Chloro-3-(trifluoromethyl)phenyl]-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (7). 
Yield: 76%, m.p. 130–132 °C, 1H-NMR (250 MHz): 6.70–8.35 (m, 7H, Ar-H), 11.47 (s, 1H, OH), 
14.20 (s, 1H, NH). 13C-NMR (75 MHz): 12.35, 113.72, 115.84, 117.59, 119.83, 124.71, 126.11, 
128.17, 130.83, 131.95, 132.66, 134.04, 148.35, 156.82, 166.27. Anal. calc. for C15H9ClF3N3OS 
(371.76): C 48.46, H 2.44, N 11.30. Found: C 48.52, H 3.37, N 11.12. 
4-Cyclohexyl-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (8). Yield: 80%. CAS: 
26028-79-5. 
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4-(3,4-Dichlorophenyl)-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (9). Yield: 83%, 
m.p. 184–185 °C, 1H-NMR (250 MHz): 6.75–6.90 (m, 3H, Ar-H), 7.23 (t, 1H, Ar-H, J = 7.4 Hz), 7.44 
(dd, 1H, Ar-H, J = 8.6 Hz, 2.4 Hz), 7.81–7.91 (m, 2H, Ar-H), 9.90 (s, 1H, OH), 14.26 (s, 1H, NH). 
13C-NMR (75 MHz): 111.35, 114.87, 118.74, 126.92, 127.78, 129.34, 129.71, 130.71, 131.08, 132.33, 
148.94, 154.49, 166.25. Anal. calc. for C14H9Cl2N3OS (338.21): C 49.72, H 2.68, N 12.42. Found: C 
49.56, H 2.55, N 12.58. 
4-(2,4-Dichlorophenyl)-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (10). Yield: 80%, 
m.p. 196–198 °C, 1H-NMR (250 MHz): 6.75–6.92 (m, 3H, Ar-H), 7.23 (t, 1H, Ar-H, J = 7.9 Hz), 
7.68–7.82 (m, 2H, Ar-H), 7.96 (d, 1H, Ar-H, J = 2.2 Hz), 9.94 (s, 1H, OH), 14.22 (s, 1H, NH).  
13C-NMR (75 MHz): 111.20, 114.38, 117.90, 126.71, 127.93, 129.27, 130.72, 131.37, 131.83, 132.12, 
133.59, 148.63, 154.82, 166.05. Anal. calc. for C14H9Cl2N3OS (338.21): C 49.72, H 2.68, N 12.42. 
Found: C 49.61, H 2.49, N 12.30. 
4-(3,5-Dichlorophenyl)-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (11). Yield: 85%, 
m.p. 296–298 °C, 1H-NMR (250 MHz): 6.73–6.93 (m, 3H, Ar-H), 7.23 (t, 1H, Ar-H, J = 7.8 Hz), 
7.62–7.68 (m, 2H, Ar-H), 7.79–7.86 (m, 1H, Ar-H), 9.87 (s, 1H, OH), 14.24 (s, 1H, NH). 13C-NMR 
(75 MHz): 113.72, 116.19, 117.70, 125.07, 126.78, 128.06, 128.50, 132.85, 135.39, 148.86, 155.75, 
166.91. Anal. calc. for C14H9Cl2N3OS (338.21): C 49.72, H 2.68, N 12.42. Found: C 49.85, H 2.50,  
N 12.29. 
4-(4-Bromo-2-chlorophenyl)-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (12). Yield: 
77%, m.p. 204–206 °C, 1H-NMR (250 MHz): 6.74–6.93 (m, 3H, Ar-H), 7.23 (t, 1H, Ar-H, J = 7.7 Hz), 
7.65–7.88 (m, 2H, Ar-H), 8.09 (d, 1H, Ar-H, J = 2.6 Hz), 9.95 (s, 1H, OH), 14.21 (s, 1H, NH). Anal. 
calc. for C14H9BrClN3OS (382.66): C 43.94, H 2.37, N 10.98. Found: C 43.81, H 2.50, N 11.13. 
4-(3-Chloro-4-methylphenyl)-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (13). Yield: 
85%, m.p. 212–214 °C, 1H-NMR (250 MHz): 2.43 (s, 3H, CH3), 6.72–6.90 (m, 3H, Ar-H), 7.14–7.28 
(m, 2H, Ar-H), 7.50 (d, 1H, Ar-H, J = 8.0 Hz), 7.60 (d, 1H, Ar-H, J = 2.2 Hz), 9.87 (s, 1H, OH), 14.15 
(s, 1H, NH). 13C-NMR (75 MHz): 18.03, 113.73, 116.11, 117.60, 125.32, 126.09, 127.64, 128.37, 
130.31, 131.94, 132.05, 135.65, 149.07, 155.73, 167.04. Anal. calc. for C15H12ClN3OS (317.79): C 
56.69, H 3.81, N 13.22. Found: C 56.82, H 3.86, N 13.02. 
4-[4-Chloro-3-(trifluoromethyl)phenyl]-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (14). 
Yield: 80%, m.p. 154–156 °C, 1H-NMR (250 MHz): 6.72–6.91 (m, 3H, Ar-H), 7.22 (t, 1H, Ar-H,  
J = 7.8 Hz), 7.70–8.10 (m, 3H, Ar-H), 9.89 (s, 1H, OH), 14.26 (s, 1H, NH). 13C-NMR (75 MHz): 
12.46, 113.89, 116.14, 117.82, 119.15, 124.17, 125.10, 128.45, 130.65, 131.28, 132.50, 133.14, 
148.98, 155.74, 166.20. Anal. calc. for C15H9ClF3N3OS (371.76): C 48.46, H 2.44, N 11.30. Found: C 
48.59, H 2.31, N 11.42. 
4-Cyclohexyl-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (15). Yield: 76%. CAS: 
26028-87-5. 
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4-(3,4-Dichlorophenyl)-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (16). Yield: 87%, 
m.p. 232–234 °C, 1H-NMR (250 MHz): 6.80 (dd, 2H, Ar-H, J = 6.7 Hz, 2.0 Hz), 7.20 (dd, 2H, Ar-H,  
J = 6.7 Hz, 2.1 Hz), 7.41 (dd, 1H, Ar-H, J = 8.6 Hz, 2.4 Hz), 7.62–7.89 (m, 2H, Ar-H), 11.37 (s, 1H, 
OH), 14.15 (s, 1H, NH). 13C-NMR (75 MHz): 111.48, 114.27, 119.22, 126.32, 127.78, 129.32, 129.93, 
131.11, 131.84, 132.63, 148.74, 154.56, 166.52. Anal. calc. for C14H9Cl2N3OS (338.21): C 49.72, H 
2.68, N 12.42. Found: C 49.67, H 2.45, N 12.33. 
4-(2,4-Dichlorophenyl)-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (17). Yield: 83%, 
m.p. 257–258 °C, 1H-NMR (250 MHz): 6.72 (dd, 2H, Ar-H, J = 6.7 Hz, 2.1 Hz), 7.14 (dd, 2H, Ar-H,  
J = 6.7 Hz, 2.1 Hz), 7.60–7.72 (m, 2H, Ar-H), 7.86 (d, 1H, Ar-H, J = 2.1 Hz), 10.11 (s, 1H, OH), 14.11 
(s, 1H, NH). 13C-NMR (75 MHz): 114.22, 114.60, 127.41, 127.88, 128.60, 130.13, 131.82, 134.18, 
149.16, 158.06, 166.76. Anal. calc. for C14H9Cl2N3OS (338.21): C 49.72, H 2.68, N 12.42. Found: C 
49.57, H 2.64, N 12.59. 
4-(3,5-Dichlorophenyl)-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (18). Yield: 82%, 
m.p. 258–260 °C, 1H-NMR (250 MHz): 6.81 (dd, 2H, Ar-H, J = 6.7 Hz, 2.1 Hz), 7.22 (dd, 2H, Ar-H,  
J = 6.7 Hz, 2.1 Hz), 7.63 (d, 2H, Ar-H, J = 1.9 Hz), 7.84 (t, 1H, Ar-H, J = 1.9 Hz), 10.17 (s, 1H, OH), 
14.15 (s, 1H, NH). 13C-NMR (75 MHz): 114.04, 114.55, 126.84, 127.95, 128.72, 132.82, 135.51, 
149.14, 157.83, 166.57. Anal. calc. for C14H9Cl2N3OS (338.21): C 49.72, H 2.68, N 12.42. Found: C 
49.89, H 2.58, N 12.59. 
4-(4-Bromo-2-chlorophenyl)-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (19). Yield: 
76%, m.p. 262–263 °C, 1H-NMR (250 MHz): 6.79 (dd, 2H, Ar-H, J = 6.7 Hz, 1.9 Hz), 7.22 (dd, 2H, 
Ar-H, J = 6.7 Hz, 2.0 Hz), 7.69 (d, 1H, Ar-H, J = 8.4 Hz), 7.80–7.87 (m, 1H, Ar-H), 8.05 (d, 1H,  
Ar-H, J = 2.1 Hz), 10.20 (s, 1H, OH), 14.18 (s, 1H, NH). Anal. calc. for C14H9BrClN3OS (382.66): C 
43.94, H 2.37, N 10.98. Found: C 44.13, H 2.28, N 10.78. 
4-(3-Chloro-4-methylphenyl)-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (20). Yield: 
78%, m.p. 263–264 °C, 1H-NMR (250 MHz): 2.47 (s, 3H, CH3), 6.77 (dd, 2H, Ar-H, J = 6.7 Hz, 2.1 
Hz), 7.20 (dd, 2H, Ar-H, J = 6.7 Hz, 2.1 Hz), 7.26 (d, 1H, Ar-H, J = 2.1 Hz), 7.48–7.60 (m, 2H, Ar-H), 
10.14 (s, 1H, OH), 14.09 (s, 1H, NH). 13C-NMR (75 MHz): 18.01, 113.98, 114.84, 126.22, 127.70, 
128.60, 130.27, 131.90, 132.18, 135.62, 149.33, 157.76, 166.74. Anal. calc. for C15H12ClN3OS 
(317.79): C 56.69, H 3.81, N 13.22. Found: C 56.51, H 3.60, N 13.04. 
4-[4-Chloro-3-(trifluoromethyl)phenyl]-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (21). 
Yield: 74%, m.p. 160–162 °C, 1H-NMR (250 MHz): 6.83–6.97 (m, 3H, Ar-H), 7.20 (t, 1H, Ar-H,  
J = 7.9 Hz), 7.65–7.92 (m, 3H, Ar-H), 10.17 (s, 1H, OH), 14.05 (s, 1H, NH). Anal. calc. for 
C15H9ClF3N3OS (371.76): C 48.46, H 2.44, N 11.30. Found: C 48.59, H 2.30, N 11.43. 
3.1.3. General Procedure for the Synthesis of 1,2,4-Triazole-Ciprofloxacin Hybrids (22–42) 
1 mmol of the respective 1,2,4-triazole derivative (1–21) was dissolved (with heating) in 40 mL of 
anhydrous ethanol and then the equimolar amount of ciprofloxacin and formaldehyde solution were 
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added. The obtained suspension was stirred at room temperature for 12 hours. The precipitate formed 
was filtered off, dried, and crystallized from ethanol to give compounds 22–42. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-cyclohexyl-3-(2-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-1,2,4-
triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (22). Yield: 70%, 
m.p. 128–130 °C, 1H-NMR (250 MHz): 1.06–2.56 (m, 15H, cyclopropyl + cyclohexyl), 2.89 (bs, 4H, 
piperazine), 3.32 (bs, 4H, piperazine), 3.81–3.85 (m, 1H, cyclopropyl), 4.46 (s, 2H, CH2), 7.06–7.65 
(m, 6H, Ar-H), 8.61 (s, 1H, Ar-H), 10.16 (s, 1H, OH), 14.92 (s, 1H, COOH). IR (ATR): 3454, 3326 
(O-H), 3062, 2962, 2861 (C-H), 1727 (C=O), 1620 (C=N), 1419 (C-O), 1324 (C=S), 1264 (O-H), 1043 
(C-F). Anal. calc. for C32H35FN6O4S (618.72): C 62.12, H 5.70, N 13.58. Found: C 62.03, H 5.91, N 13.40. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3,4-dichlorophenyl)-3-(2-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (23). Yield: 
68%, m.p. 237–238 °C, 1H-NMR (250 MHz): 1.12–1.14 (m, 2H, cyclopropyl), 1.20–1.24 (m, 2H, 
cyclopropyl), 2.85 (bs, 4H, piperazine), 3.34 (bs, 4H, piperazine), 3.82–3.86 (m, 1H, cyclopropyl), 
4.47 (s, 2H, CH2), 6.84–7.68 (m, 9H, Ar-H), 8.65 (s, 1H, Ar-H), 10.12 (s, 1H, OH), 15.02 (s, 1H, 
COOH). IR (ATR): 3482 (O-H), 3122, 2905 (C-H), 1747 (C=O), 1613 (C=N), 1423 (C-O), 1310 
(C=S), 1253 (O-H), 1011 (C-F). Anal. calc. for C32H27Cl2FN6O4S (681.56): C 56.39, H 3.99, N 12.33. 
Found: C 56.56, H 4.18, N 12.05. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(2,4-dichlorophenyl)-3-(2-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (24). Yield: 
72%, m.p. 220–221 °C, 1H-NMR (250 MHz): 1.08–1.12 (m, 2H, cyclopropyl), 1.18–1.22 (m, 2H, 
cyclopropyl), 2.86 (bs, 4H, piperazine), 3.32 (bs, 4H, piperazine), 3.81–3.84 (m, 1H, cyclopropyl), 
4.52 (s, 2H, CH2), 6.87-7.68 (m, 9H, Ar-H), 8.68 (s, 1H, Ar-H), 10.21 (s, 1H, OH), 14.95 (s, 1H, 
COOH). IR (ATR): 3480 (O-H), 3057, 2933 (C-H), 1722 (C=O), 1633 (C=N), 1429 (C-O), 1328 
(C=S), 1258 (O-H), 1018 (C-F). Anal. calc. for C32H27Cl2FN6O4S (681.56): C 56.39, H 3.99, N 12.33. 
Found: C 56.59, H 3.86, N 12.25. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3,5-dichlorophenyl)-3-(2-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (25). Yield: 
73%, m.p. 224–226 °C, 1H-NMR (250 MHz): 1.15–1.18 (m, 2H, cyclopropyl), 1.25–1.29 (m, 2H, 
cyclopropyl), 2.80 (bs, 4H, piperazine), 3.35 (bs, 4H, piperazine), 3.80–3.84 (m, 1H, cyclopropyl), 
4.44 (s, 2H, CH2), 6.94–7.75 (m, 9H, Ar-H), 8.68 (s, 1H, Ar-H), 10.18 (s, 1H, OH), 15.02 (s, 1H, 
COOH). IR (ATR): 3437 (O-H), 2983, 2835 (C-H), 1725 (C=O), 1643 (C=N), 1432 (C-O), 1310 
(C=S), 1254 (O-H), 1041 (C-F). Anal. calc. for C32H27Cl2FN6O4S (681.56): C 56.39, H 3.99, N 12.33. 
Found: C 56.50, H 4.10, N 12.42. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(4-bromo-2-chlorophenyl)-3-(2-hydroxyphenyl)-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (26). 
Yield: 66%, m.p. 214–216 °C, 1H-NMR (250 MHz): 1.20–1.23 (m, 2H, cyclopropyl), 1.28–1.32 (m, 
2H, cyclopropyl), 2.80 (s, 4H, piperazine), 3.41 (s, 4H, piperazine), 3.81–3.85 (m, 1H, cyclopropyl), 
4.56 (s, 2H, CH2), 6.86–7.74 (m, 9H, Ar-H), 8.68 (s, 1H, Ar-H), 10.21 (s, 1H, OH), 14.85 (s, 1H, 
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COOH). IR (ATR): 3473, 3364 (O-H), 3084, 2872 (C-H), 1724 (C=O), 1626 (C=N), 1432 (C-O), 1325 
(C=S), 1272 (O-H), 1008 (C-F). Anal. calc. for C32H27BrClFN6O4S (726.01): C 52.94, H 3.75, N 
11.58. Found: C 52.82, H 3.61, N 11.70. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3-chloro-4-methylphenyl)-3-(2-hydroxyphenyl)-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (27). 
Yield: 75%, m.p. 237–238 °C, 1H-NMR (250 MHz): 1.12–1.14 (m, 2H, cyclopropyl), 1.21–1.23 (m, 
2H, cyclopropyl), 2.24 (s, 3H, CH3), 2.92 (bs, 4H, piperazine), 3.41 (bs, 4H, piperazine), 3.82-3.85 (m, 
1H, cyclopropyl), 4.51 (s, 2H, CH2), 6.87-7.68 (m, 9H, Ar-H), 8.60 (s, 1H, Ar-H), 10.19 (s, 1H, OH), 
15.00 (s, 1H, COOH). IR (ATR): 3469 (O-H), 3085, 2958, 2852 (C-H), 1740 (C=O), 1634 (C=N), 
1419 (C-O), 1320 (C=S), 1276 (O-H), 1033 (C-F). Anal. calc. for C33H30ClFN6O4S (661.14): C 59.95, 
H 4.57, N 12.71. Found: C 60.12, H 4.53, N 12.79. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(4-chloro-3-trifluoromethylphenyl)-3-(2-hydroxyphenyl)-5-thioxo-
4,5-dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(28). Yield: 63%, m.p. 230–231 °C, 1H-NMR (250 MHz): 1.17–1.20 (m, 2H, cyclopropyl), 1.27–1.31 
(m, 2H, cyclopropyl), 2.90 (s, 4H, piperazine), 3.31 (s, 4H, piperazine), 3.82–3.86 (m, 1H, cyclopropyl), 
4.58 (s, 2H, CH2), 6.79–7.72 (m, 9H, Ar-H), 8.66 (s, 1H, Ar-H), 10.18 (s, 1H, OH), 14.89 (s, 1H, 
COOH). IR (ATR): 3459 (O-H), 3103, 3015, 2891 (C-H), 1729 (C=O), 1631 (C=N), 1429 (C-O), 1323 
(C=S), 1274 (O-H), 1046 (C-F). Anal. calc. for C33H27ClF4N6O4S (715.12): C 55.42, H 3.81, N 11.75. 
Found: C 55.63, H 3.70, N 11.91. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-cyclohexyl-3-(3-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-1,2,4-
triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (29). Yield: 71%, 
m.p. 246–248 °C, 1H-NMR (250 MHz): 1.11–2.68 (m, 15H, cyclopropyl + cyclohexyl), 2.84 (s, 4H, 
piperazine), 3.36 (bs, 4H, piperazine), 3.82–3.87 (m, 1H, cyclopropyl), 4.54 (s, 2H, CH2), 6.94–7.58 
(m, 6H, Ar-H), 8.66 (s, 1H, Ar-H), 9.87 (s, 1H, OH), 14.97 (s, 1H, COOH). IR (ATR): 3506, 3365 (O-H), 
3050, 2962, 2901 (C-H), 1743 (C=O), 1621 (C=N), 1416 (C-O), 1315 (C=S), 1279 (O-H), 1026 (C-F). 
Anal. calc. for C32H35FN6O4S (618.72): C 62.12, H 5.70, N 13.58. Found: C 62.19, H 5.84, N 13.71. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3,4-dichlorophenyl)-3-(3-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (30). Yield: 
70%, m.p. 214–216 °C, 1H-NMR (250 MHz): 1.13–1.17 (m, 2H, cyclopropyl), 1.24–1.28 (m, 2H, 
cyclopropyl), 2.84 (bs, 4H, piperazine), 3.36 (bs, 4H, piperazine), 3.82–3.87 (m, 1H, cyclopropyl), 
4.49 (s, 2H, CH2), 6.84–7.75 (m, 9H, Ar-H), 8.65 (s, 1H, Ar-H), 9.87 (s, 1H, OH), 14.89 (s, 1H, 
COOH). IR (ATR): 3454 (O-H), 3105, 3023, 2882 (C-H), 1726 (C=O), 1631 (C=N), 1433 (C-O), 1307 
(C=S), 1271 (O-H), 1039 (C-F). Anal. calc. for C32H27Cl2FN6O4S (681.56): C 56.39, H 3.99, N 12.33. 
Found: C 56.57, H 4.14, N 12.27. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(2,4-dichlorophenyl)-3-(3-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (31). Yield: 
78%, spectral data published in Ref. [6] 
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1-Cyclopropyl-6-fluoro-7-[4-{[4-(3,5-dichlorophenyl)-3-(3-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (32). Yield: 
74%, spectral data published in Ref. [6] 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(4-bromo-2-chlorophenyl)-3-(3-hydroxyphenyl)-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (33). 
Yield: 67%, m.p. 246–248 °C, 1H-NMR (250 MHz): 1.12–1.17 (m, 2H, cyclopropyl), 1.21–1.24 (m, 
2H, cyclopropyl), 2.89 (bs, 4H, piperazine), 3.32 (bs, 4H, piperazine), 3.82–3.86 (m, 1H, cyclopropyl), 
4.47 (s, 2H, CH2), 6.95–7.84 (m, 9H, Ar-H), 8.62 (s, 1H, Ar-H), 9.93 (s, 1H, OH), 14.82 (s, 1H, 
COOH). IR (ATR): 3469 (O-H), 3005, 2950 (C-H), 1720 (C=O), 1631 (C=N), 1427 (C-O), 1328 
(C=S), 1256 (O-H), 1027 (C-F). Anal. calc. for C32H27BrClFN6O4S (726.01): C 52.94, H 3.75, N 
11.58. Found: C 53.12, H 3.72, N 11.42. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3-chloro-4-methylphenyl)-3-(3-hydroxyphenyl)-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (34). 
Yield: 73%, m.p. 204–206 °C, 1H-NMR (250 MHz): 1.16–1.20 (m, 2H, cyclopropyl), 1.25–1.28 (m, 
2H, cyclopropyl), 2.41 (s, 3H, CH3), 2.72 (bs, 4H, piperazine), 3.32 (bs, 4H, piperazine), 3.80–3.85 (m, 
1H, cyclopropyl), 4.46 (s, 2H, CH2), 6.86–7.75 (m, 9H, Ar-H), 8.70 (s, 1H, Ar-H), 9.84 (s, 1H, OH), 
14.96 (s, 1H, COOH). IR (ATR): 3504, 3375 (O-H), 3042, 2910 (C-H), 1711 (C=O), 1627 (C=N), 
1441 (C-O), 1317 (C=S), 1250 (O-H), 1022 (C-F). Anal. calc. for C33H30ClFN6O4S (661.14): C 59.95, 
H 4.57, N 12.71. Found: C 59.78, H 4.62, N 12.82. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(4-chloro-3-trifluoromethylphenyl)-3-(3-hydroxyphenyl)-5-thioxo-
4,5-dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(35). Yield: 63%, m.p. 168–170 °C, 1H-NMR (250 MHz): 1.20–1.24 (m, 2H, cyclopropyl), 1.28–1.31 
(m, 2H, cyclopropyl), 2.90 (bs, 4H, piperazine), 3.35 (bs, 4H, piperazine), 3.83-3.86 (m, 1H, cyclopropyl), 
4.67 (s, 2H, CH2), 6.87–7.63 (m, 9H, Ar-H), 8.69 (s, 1H, Ar-H), 9.81 (s, 1H, OH), 14.73 (s, 1H, 
COOH). IR (ATR): 3483 (O-H), 2982, 2927, 2831 (C-H), 1730 (C=O), 1642 (C=N), 1437 (C-O), 1319 
(C=S), 1272 (O-H), 1023 (C-F). Anal. calc. for C33H27ClF4N6O4S (715.12): C 55.42, H 3.81, N 11.75. 
Found: C 55.49, H 3.69, N 11.64. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-cyclohexyl-3-(4-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-1,2,4-
triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (36). Yield: 74%, 
m.p. 256–258 °C, 1H-NMR (250 MHz): 1.01–2.60 (m, 15H, cyclopropyl + cyclohexyl), 2.92 (bs, 4H, 
piperazine), 3.30 (bs, 4H, piperazine), 3.81–3.87 (m, 1H, cyclopropyl), 4.62 (s, 2H, CH2), 6.98–7.53 
(m, 6H, Ar-H), 8.63 (s, 1H, Ar-H), 9.95 (s, 1H, OH), 15.06 (s, 1H, COOH). IR (ATR): 3512 (O-H), 
3100, 2944, 2875 (C-H), 1730 (C=O), 1621 (C=N), 1417 (C-O), 1316 (C=S), 1254 (O-H), 1046 (C-F). 
Anal. calc. for C32H35FN6O4S (618.72): C 62.12, H 5.70, N 13.58. Found: C 62.21, H 5.54, N 13.42. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3,4-dichlorophenyl)-3-(4-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (37). Yield: 
73%, m.p. 205–206 °C, 1H-NMR (250 MHz): 1.16–1.20 (m, 2H, cyclopropyl), 1.27–1.31 (m, 2H, 
cyclopropyl), 2.74 (bs, 4H, piperazine), 3.28 (bs, 4H, piperazine), 3.82–3.86 (m, 1H, cyclopropyl), 
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4.68 (s, 2H, CH2), 6.83–7.76 (m, 9H, Ar-H), 8.73 (s, 1H, Ar-H), 10.74 (s, 1H, OH), 14.92 (s, 1H, 
COOH). IR (ATR): 3495 (O-H), 2972, 2869 (C-H), 1741 (C=O), 1628 (C=N), 1423 (C-O), 1329 
(C=S), 1260 (O-H), 1038 (C-F). Anal. calc. for C32H27Cl2FN6O4S (681.56): C 56.39, H 3.99, N 12.33. 
Found: C 56.51, H 4.10, N 12.23. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(2,4-dichlorophenyl)-3-(4-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (38). Yield: 
68%, m.p. 234–236 °C, 1H-NMR (250 MHz): 1.20–1.124 (m, 2H, cyclopropyl), 1.33–1.36 (m, 2H, 
cyclopropyl), 2.94 (s, 4H, piperazine), 3.42 (s, 4H, piperazine), 3.81–3.85 (m, 1H, cyclopropyl), 4.56 
(s, 2H, CH2), 6.84–7.76 (m, 9H, Ar-H), 8.69 (s, 1H, Ar-H), 10.18 (s, 1H, OH), 15.03 (s, 1H, COOH). 
IR (ATR): 3479 (O-H), 3025, 2902, 2872 (C-H), 1738 (C=O), 1627 (C=N), 1419 (C-O), 1324 (C=S), 
1259 (O-H), 1027 (C-F). Anal. calc. for C32H27Cl2FN6O4S (681.56): C 56.39, H 3.99, N 12.33. Found: 
C 56.50, H 3.83, N 12.37. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3,5-dichlorophenyl)-3-(4-hydroxyphenyl)-5-thioxo-4,5-dihydro-1H-
1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (39). Yield: 
64%, m.p. 254–256 °C, 1H-NMR (250 MHz): 1.15–1.19 (m, 2H, cyclopropyl), 1.28–1.31 (m, 2H, 
cyclopropyl), 2.99 (bs, 4H, piperazine), 3.38 (bs, 4H, piperazine), 3.83–3.86 (m, 1H, cyclopropyl), 
4.68 (s, 2H, CH2), 6.91–7.77 (m, 9H, Ar-H), 8.60 (s, 1H, Ar-H), 10.21 (s, 1H, OH), 14.76 (s, 1H, 
COOH). IR (ATR): 3518 (O-H), 3075, 2942 (C-H), 1717 (C=O), 1629 (C=N), 1456 (C-O), 1314 
(C=S), 1272 (O-H), 1016 (C-F). Anal. calc. for C32H27Cl2FN6O4S (681.56): C 56.39, H 3.99, N 12.33. 
Found: C 56.47, H 3.80, N 12.43. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(4-bromo-2-chlorophenyl)-3-(4-hydroxyphenyl)-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (40). 
Yield: 67%, m.p. 242–244 °C, 1H-NMR (250 MHz): 1.23–1.27 (m, 2H, cyclopropyl), 1.35–1.38 (m, 
2H, cyclopropyl), 2.84 (bs, 4H, piperazine), 3.39 (bs, 4H, piperazine), 3.78–3.83 (m, 1H, cyclopropyl), 
4.60 (s, 2H, CH2), 6.85–7.69 (m, 9H, Ar-H), 8.73 (s, 1H, Ar-H), 10.20 (s, 1H, OH), 14.87 (s, 1H, 
COOH). IR (ATR): 3450 (O-H), 3122, 2952, 2920 (C-H), 1720 (C=O), 1634 (C=N), 1438 (C-O), 1320 
(C=S), 1273 (O-H), 1033 (C-F). Anal. calc. for C32H27BrClFN6O4S (726.01): C 52.94, H 3.75, N 
11.58. Found: C 53.08, H 3.72, N 11.42. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(3-chloro-4-methylphenyl)-3-(4-hydroxyphenyl)-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (41). 
Yield: 72%, m.p. 217–219 °C, 1H-NMR (250 MHz): 1.14–1.18 (m, 2H, cyclopropyl), 1.30–1.35 (m, 
2H, cyclopropyl), 2.47 (s, 3H, CH3), 2.96 (s, 4H, piperazine), 3.43 (s, 4H, piperazine), 3.82–3.86 (m, 
1H, cyclopropyl), 4.66 (s, 2H, CH2), 6.93–7.76 (m, 9H, Ar-H), 8.68 (s, 1H, Ar-H), 10.11 (s, 1H, OH), 
14.96 (s, 1H, COOH). IR (ATR): 3506 (O-H), 3005, 2948, 2781 (C-H), 1740 (C=O), 1638 (C=N), 
1441 (C-O), 1341 (C=S), 1264 (O-H), 1018 (C-F). Anal. calc. for C33H30ClFN6O4S (661.14): C 59.95, 
H 4.57, N 12.71. Found: C 59.84, H 4.72, N 12.65. 
1-Cyclopropyl-6-fluoro-7-[4-{[4-(4-chloro-3-trifluoromethylphenyl)-3-(4-hydroxyphenyl)-5-thioxo-
4,5-dihydro-1H-1,2,4-triazol-1-yl]methyl}piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic 
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acid (42). Yield: 63%, m.p. 198–200 °C, 1H-NMR (250 MHz): 1.20–1.124 (m, 2H, cyclopropyl), 
1.34–1.38 (m, 2H, cyclopropyl), 2.87 (s, 4H, piperazine), 3.38 (s, 4H, piperazine), 3.82–3.86 (m, 1H, 
cyclopropyl), 4.57 (s, 2H, CH2), 6.90–7.76 (m, 9H, Ar-H), 8.66 (s, 1H, Ar-H), 10.04 (s, 1H, OH), 
14.94 (s, 1H, COOH). IR (ATR): 3487 (O-H), 2984, 2847 (C-H), 1724 (C=O), 1619 (C=N), 1438 (C-O), 
1317 (C=S), 1269 (O-H), 1030 (C-F). Anal. calc. for C33H27ClF4N6O4S (715.12): C 55.42, H 3.81, N 
11.75. Found: C 55.47, H 3.73, N 11.86. 
3.2. Antimicrobial Activity Evaluation 
The antimicrobial activity of the compounds was tested on the Gram-positive strains 
(Staphylococcus aureus ATCC 25923, Staphylococcus aureus ATCC 6538, Staphylococcus aureus 
Microbank 14001, Staphylococcus epidermidis ATCC 12228, Bacillus subtilis ATCC 6633, Bacillus 
cereus ATCC 10876, Micrococcus luteus ATCC 10240), and on the Gram-negative strains 
(Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 13883, Proteus mirabilis ATCC 12453, 
and Pseudomonas aeruginosa ATCC 9027). Ciprofloxacin and vancomycin were used as control 
antibacterial agents. Microbial suspensions with an optical density of 0.5 McFarland standard  
150 × 106 CFU/mL (CFU—colony forming units) were prepared in sterile 0.85% NaCl. All stock 
solutions of the tested compounds were dissolved in dimethyl sulfoxide (DMSO). The medium with 
DMSO in the final concentration and without the tested compounds served as a control—no microbial 
growth inhibition was observed. Preliminary antibacterial in vitro potency of the tested compounds 
was screened using an agar dilution method on the basis of the growth inhibition on a Mueller-Hinton 
agar to which the tested compounds in concentration of 1000 µg/mL were added. In the next assay  
in vitro antibacterial activity of the compounds with inhibitory effect was determined by a broth 
microdilution method. The 96-well microplates were used; 198 μL of Mueller–Hinton broth with a 
series of two-fold dilutions of the tested compound in the range of the final concentrations from  
0.24–1000 μg/mL was inoculated with 2 μL of microbial suspension. After incubation (at 37 °C for  
18 h), spectrophotometric measurements of optical density (OD600) of the bacterial cultures with the 
tested compounds were performed in order to determine MIC. OD600 of bacterial cultures in the 
medium without the tested compounds was used as a control. The activity was expressed as the 
minimal concentration of the compound that inhibits the visible growth of the bacteria (MIC, minimal 
inhibitory concentration). The MBC (minimal bactericidal concentration), defined as the lowest 
concentration of each compound that resulted in >99.9% reduction in CFU of the initial inoculum, was 
also assessed. 
3.3. Cytotoxicity Assay 
HEK-293 (human embryonic kidney) cells were obtained from the American Type Culture 
Collection (ATCC CRL-1573) and were grown in Minimal Essential Medium (MEM; Sigma-Aldrich, 
Saint Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich). 100 U/mL 
of penicillin and 100 μg/mL of streptomycin were added to the media. The cell cultures were incubated 
at 37 °C in a humidified atmosphere with 5% CO2. The investigated compounds were dissolved in 
dimethyl sulfoxide (50 mg/mL) and then diluted in cell culture media supplemented with 2% FBS. 
HEK-293 cells were placed into 96-well plastic plates (Nunc, Roskilde, Denmark) at a cell density of  
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3 × 105 cells per well. After 24 h of incubation at 37 °C, the media were removed and cells treated with 
the derivatives, diluted in media at final concentrations of 2–500 μg/mL. Cell cultures were incubated at 
37 °C for 72 h. The cytotoxicity was estimated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) that is cleaved into a colored formazan product by metabolically active cells, 
according to the assay described by Takenouchi and Munekata [15]. The quantity of the formazan 
product was measured in an automatic plate reader. From the obtained results the EC50 (concentration 
of the substance which inhibits cells growth in 50% in proportion to the growth of control cells) values 
were calculated. The results were given as mean ± SD of three independent experiments. 
3.4. Enzymatic Assays 
The inhibitory activity of DNA gyrase and topoisomerase IV from E. coli was evaluated using a 
gyrase supercoling assay kit and a topoisomerase IV decatenation kit (both kits obtained from 
Inspiralis, Norwich, UK). Briefly, supercoiled pBR322 plasmid DNA (0.5 μg) was incubated with 1 U 
gyrase, in the dedicated supercoiling assay buffer supplied by the manufacturer, in the presence of 
varying concentrations of the test compounds. Reactions were carried out at 37 °C for 1 h and then 
terminated by the addition of an equal volume of 2× STOP Buffer (40% sucrose, 100 mM Tris Cl pH 7.5, 
1 mM EDTA, and 0.5 mg/mL bromophenol blue) and chloroform/isoamyl alcohol. Samples were 
vortexed, centrifuged and run through a 15 cm 1% agarose gel in TAE buffer (40 mM Tris-acetate,  
2 mM EDTA) for 3 h at 50 V. Gels were stained with ethidium bromide and visualized under UV light. 
The decatenation assay was performed using an E. coli topoisomerase IV decatenation kit (Inspiralis). 
Interlinked kDNA substrate (0.5 μg) was incubated with 1 U topoisomerase IV (Inspiralis), in the 
dedicated decatenation assay buffer supplied by the manufacturer, in the presence of varying 
concentrations of the test compounds. Reactions were carried out at 37 °C for 1 h and then terminated 
by the addition of equal volume of 2× STOP Buffer (40% sucrose, 100 mM Tris-Cl pH 7.5, 1 mM 
EDTA, and 0.5 mg/mL bromophenol blue) and chloroform/isoamyl alcohol. Samples were vortexed, 
centrifuged and run through a 15 cm 1% agarose gel in TAE buffer for 1.5 h at 80 V. Gels were stained 
with ethidium bromide and visualized under UV light. Concentrations of inhibitor that prevented 50% 
of the kinetoplast DNA from being converted into decatenated minicircles (IC50 values) were 
determined by plotting the results obtained from the densytometric analyses of the gel images using 
Quantity One software (BioRad). 
4. Conclusions 
We have examined several novel CPX-triazole hybrids against pathogenic and opportunistic 
bacteria. A number of these compounds displayed enhanced potency both against Gram-negative and  
Gram-positive bacteria, including MRSA strain. What is important, their antibacterial effect was 
achieved at completely non-toxic concentrations for human cells. Moreover, it has been shown that the 
increased activity is not caused by the increased affinity of the obtained compounds towards bacterial 
type II topoisomerases constituting the primary molecular targets for fluoroquinolones. The research has 
also proven that the presence of the disubstituted phenyl ring connected to the 1,2,4-triazole skeleton 
determines stronger antibacterial activity rather towards Gram-positive than Gram-negative bacteria. 
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